top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 07 March 2022

Review of COVID-19 in Children Admitted to King Fahad Hospital, Albaha, Saudi Arabia in 2020

Abdulmajid Almawazini, Ahmed Obaidalla Alghamdi, Sinan Alnashi, Mohammed Seif Aldin Suliman Ahmed, Ali Alsharkawy, Chafik Ibrahim Hassan, Mohammed Ahmed Alghamdi, Khalid Mohammad Alshumrani, Ahmed Yahiya, Mohammed Jaman, Abdulla Nakhali, Osama Alghamdi, Essam Alghamdi, Mohammed Zahrani, Hazem Almawazini, Mohammad Almawazini, Mohammad Alshumrani, Tamer Ata, Marjorrie Madco, Aesa PayonGa, Thara Kundoly

KFH Albaha, Albaha University, Cairo University, Infection Control Department

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 18-23

Keywords: COVID-19, SARS-CoV-2


Background: The coronavirus disease (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified at the end of 2019 in Wuhan City, China and then spread worldwide. Objectives: The study aimed to evaluate COVID-19 symptoms, signs, management, and outcomes in admitted children. Methods: This retrospective cohort study was conducted at King Fahad Hospital, Albaha, Saudi Arabia, which is designated as the center for COVID-19 patients. Data were collected retrospectively between Apr 2020 and Mar 2021. The protocols of health authorities in Saudi Arabia were used for the diagnosis and management of all patients. Results: Positive test results were confirmed in 95 patients. Of these, 44 (46%) were males and 51 (54%) were females. Fever, cough, nasal congestion, sore throat, myalgia, and upper respiratory tract infections were the most common symptoms. The common comorbidities in this cohort were respiratory diseases (19%), type1 diabetes mellitus (16%), followed by obesity (11%), chronic kidney disease (4%), congenital heart diseases (2%), while in (48%) pts no comorbidity factors were reported. Fever was the most frequent symptom, reported in 95% of patients. Multisystem inflammatory syndrome (MIS-C) has been reported in one patient. Guillain-Barre syndrome was reported in one female patient and Kawasaki symptoms in one male patient. No mortality was reported. Conclusion: Most children with COVID-19 presented with mild clinical manifestations and good outcomes. No mortality was reported in this study. Obesity is a serious comorbidity and risk factor for severe diseases.


  1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med, 2020 Mar 26;382(13):1199-1207.  doi: 10.1056/ NEJMoa 2001316. Epub 2020 Jan 29.

  2. Riccardo Castagnoli, MD; Martina Votto, MD; Amelia Licari, MD; Ilaria Brambilla, MD, PhD; Raffaele Bruno, MD; Stefano Perlini, MD; Francesca Rovida, PhD; Fausto Baldanti, MD; Gian Luigi Marseglia, MD. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents A Systematic Review.JAMA Pediatr. 2020; 174(9):882-889. Doi: 10.1001/jama pediatrics.2020.1467 published online April 22, 2020].

  3. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. Preprint. Posted online March 27, 2020. medRxiv. doi:10.1101/2020.03.03.20028423].

  4. World Health Organization (WHO). WHO Director-General's opening remarks at the media briefing on COVID-19, 11 March 2020. Available at: https: // dg/ speeches / detail/ who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19,11-march-2020 (Accessed on May 01, 2020).

  5. World Health Organization. COVID-19 clinical management. Living guidance. World Health Organization 2021. This work is available under the CC BY-NC-SA 3.0 IGO licence. WHO reference number: WHO/2019-nCoV/clinical/2021.1 Lancet Child Adolesc Health, 2020 Sep;4(9):653-661.  doi: 10.1016/S2352 -4642 (20) 30177-2. Epub 2020 Jun 25.

  6. American Academy of Pediatrics. Post-COVID-19 conditions in children and adolescents. AAP. Available at

  7. R Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children with Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr,doi:10.1001/jamapediatrics.2020.1948. [PubMed].

  8. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19. An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr Infect DisJ. 2020 May;39(5):355-368.  doi: 10.1097/INF.0000000000002660.

  9. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics doi: 10.1542/peds.2020-0702. [Internet]

  10. Timothy G.Singer MD, MS. Karen D. Evankovich PhD. Kristen Fisher DO. Gail J.Demmler-Harrison MD. Sarah R. Risen MD. Coronavirus Infections in the Nervous System of Children: A Scoping Review Making the Case for Long-Term Neurodevelopmental Surveillance, pediatrneurol. 2021.01.007.

  11. De Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis j. 2020 Sep;20(9):1034-1042.  doi: 10.1016/S1473-3099(20)30371-6. Epub 2020 May 15

  12. Sophia Tsabouri, MD, PhD. Ekaterini Siomou, MD, PhD. Risk Factors for Severity in Children with Coronavirus Disease 2019, A Comprehensive Literature Review. Published:July 30, 2020 DOI:https:// pcl.2020.07.014. Review article, P321-338, Feb 01, 2021.

  13. Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk Factors of Severe Disease and Efficacy of Treatment in Patients Infected with COVID-19: A Systematic Review, Meta-Analysis and Meta-Regression Analysis. Clin Infect Dis 2020. doi: 10.1093/cid/ ciaa576 [Epub ahead of print]. [Internet] [PMC free article] [PubMed]

  14. Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study.  Lancet Infect Dis 2021 May;21(5):617-628.  doi: 10.1016/S1473-3099(20)30981-6. Epub 2021 Jan 18.

  15. Brandon Michael Henry, Giuseppe Lippi and Mario Plebani.  Laboratory abnormalities in children with novel coronavirus disease 2019, from the journal Clinical Chemistry and Laboratory Medicine (CCLM). Published by De Gruyter March 16, 2020.

  16. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob, 2020 May 15;19(1):18.  doi: 10.1186/s12941-020-00362-2.

  17. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. june 18, N Engl J Med 2020; 382:e102.DOI: 10.1056/NEJMoa2007621

  18. Mehra M, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020 Jun doi: 10.1016/S0140-6736(20)31324-6. [Internet] [PMC free article] [PubMed].

  19. Shen KL, Yang YH, Jiang RM, Wang TY, Zhao DC, Jiang Y, et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition). World J Pediatr, 2020 Jun;16(3):232-239.  doi: 10.1007/s12519-020-00362-4.

  20. Abdullah A.Algaissi, Naif Khalaf Alharbi, Mazen Hassanain, Anwar M.Hashem. Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience. J Infect Public Health, 2020 Jun;13(6):834-838.  doi: 10.1016/j. jiph. 2020.04.016. Epub 2020 May 11.

  21. WMA Declaration of Helsinki, ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the: 29th WMA General Assembly, Tokyo, Japan, October 1975. 35th WMA General Assembly, Venice, Italy, October 1983. 41st WMA General Assembly, Hong Kong, September 1989. 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996. 52nd WMA General Assembly, Edinburgh, Scotland,October2000, 53rd WMA General Assembly, Washington DC, USA, October 2002 (Note of Clarification added). 55th WMA General Assembly, Tokyo, Japan, October 2004 (Note of Clarification added). 59th WMA General Assembly, Seoul, Republic of Korea,October,2008 64th WMA General Assembly, Fortaleza, Brazil, October 2013.

bottom of page